Tekla Life Sciences Investors
HQL · NYSE
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 120.1% | 23.6% | -29.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 46.4% | 82.6% | 86.5% |
| EBITDA | $0 | $0 | -$0 | $0 |
| % Margin | 100.6% | 126.8% | -318.9% | 152.5% |
| Net Income | $0 | $0 | -$0 | $0 |
| % Margin | 98.4% | 56.8% | -328.3% | 143.3% |
| EPS Diluted | 3.04 | 0.79 | -4.07 | 2.66 |
| % Growth | 284.8% | 119.4% | -253% | – |
| Operating Cash Flow | – | $0 | $0 | $0 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | $0 | $0 | $0 |